Results 211 to 220 of about 295,503 (301)
Organoid Brain‐Machine‐Interface Devices for Central Nervous System Repair
We envision organoid brain‐machine‐interface (Organoid‐BMI) devices as new biohybrid bidirectional communication pathways to connect the human CNS and the external world for personalized CNS repair and regeneration. ABSTRACT Central nervous system (CNS) repair and regeneration suffer from tremendous clinical challenges due to current limitations in ...
Yantao Xing +10 more
wiley +1 more source
Variable Speech Cueing Effects in Talkers With Parkinson's Disease. [PDF]
Kim D +5 more
europepmc +1 more source
Chronic Disease Monitoring Using Advanced Compliant Materials for Bioelectronics
Compliant bioelectronic systems enable continuous monitoring of chronic disease through soft, stretchable materials and tissue‐conformal designs that support stable electrophysiological, mechanical, and biochemical sensing. Integration of diverse sensing modalities with thoughtful material selection, device architectures, and advanced fabrication ...
Han Kim +7 more
wiley +1 more source
Commentary on Gut Microbiome-Metabolome Alterations in Advanced Parkinson's Disease With Motor Complications. [PDF]
Rashid H.
europepmc +1 more source
Cerebral blood flow responses to dorsal and ventral STN DBS correlate with gait and balance responses in Parkinson\u27s disease [PDF]
Campbell, Meghan C +13 more
core +1 more source
Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models
CB1 receptor (CB1R) expression was significantly reduced in the hippocampus, medial frontal gyrus, and superior temporal gyrus of Alzheimer's patients. CB1R levels negatively correlated with amyloid‐β and tau pathology. In addition, CB1R expression was also reduced in the cortex of 5xFAD mice and in the hippocampus of Tg4‐42 mice.
Nike von Borcke +4 more
wiley +1 more source
Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease. [PDF]
Kofoed RH +7 more
europepmc +1 more source
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng +4 more
wiley +1 more source

